Epigenetics Diagnostics Market To Reach $39.15 Billion By 2030

Epigenetics Diagnostics Market Growth & Trends

The global epigenetics diagnostic market size is expected to reach USD 39.15 billion by 2030, expanding at a CAGR of 15.10% over the forecast period, according to a new study by Grand View Research, Inc. The growth is attributed to the rising incidence of major depressive disorder (MDD). According to WHO, in 2023, around 5% of adults suffer from depressive disorder. Furthermore, according to a study published by NCBI in 2022, around 280 million people are affected by MDD across the globe. Additionally, technological advancement in the field of epigenetic drug discovery is also contributing to the growth. A study published by BioMed Central Ltd. states that there is an increasing inclination towards selective isoform inhibitor construction to produce anti-tumor effects.

Moreover, increasing investment from public and private organizations in the field of epigenetics is anticipated to drive the market during 2023-2030. For instance, in March 2023, Chroma Medicine, Inc., a leader in single-dose epigenetic editing systems, completed a USD 135 million Series B funding. The financing was led by Google Ventures for the advancement in the field of epigenetic editing technology.

Key players in the industry are adopting various strategies to strengthen their market position and expand their customer base. For instance, in May 2022, Cardio Diagnostics, Inc., and Mana Capital Acquisition Corp. entered a business agreement. The goal of this agreement was to create a publicly listed company to transform cardiovascular disease through the application of epigenetics. Moreover, in February 2022, Element Bioscience, Inc., and Dovetail Genomics announced a partnership to demonstrate the performance and value of Dovetail’s next-generation sequencing library prep service on Element’s AVITI system.

The COVID-19 pandemic has positively impacted the market by creating opportunities for epigenetics researchers to study the impact of the COVID-19 virus on DNA methylation changes and myeloid differentiation. A study published by NCBI in 2022 states that epigenetic modification not only plays a crucial role in the maintenance of cellular homeostasis and the genome but also provides information about the cause and development of virus infection.

 Request a free sample copy or view report summary: Epigenetics Diagnostics Market Report

Epigenetics Diagnostics Market Report Highlights

• Based on product, the reagent segment dominated the market with a share of 31.50% in 2022. The growth is attributed to the rising demand for reagents in epigenetic research studies.

• Based on technology, the DNA methylation segment accounted for the largest revenue share of 46.73% in 2022, owing to its increasing demand in chronic disease treatment.

• Based on application, the oncology application segment accounted for the largest revenue share of 69.23% in 2022. The segment growth is attributed to the increasing demand for epigenetics research in the field of cancer owing to its growing incidences.

• North America dominated the market with a revenue share of 38.18% in 2022, owing to the presence of prominent market players and technologically advanced healthcare infrastructure. Moreover, rising awareness coupled with high R&D expenditure is anticipated to drive growth over the forecast period.

• Some of the major players in the market are Roche Diagnostics, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., Novartis AG, Element Biosciences, Inc., Dovetail Genomics LLC., Illumina, Inc., ValiRx Plc., and Abcam plc.

Epigenetics Diagnostics Market Segmentation

Grand View Research has segmented the global epigenetics diagnostics market report on the basis of product, technology, application, and region:

Epigenetics Diagnostics Product Outlook (Revenue in USD Million; 2018 - 2030)

• Reagents

• Kits

• Chip sequencing kit

• Whole Genomic Amplification kit

• Bisulfite Conversion kit

• RNA sequencing kit

• Others

• Instruments

• Enzymes

• Services

Epigenetics Diagnostics Technology Outlook (Revenue in USD Million; 2018 - 2030)

• DNA Methylation

• Reagents

• Kits

• Instruments

• Enzymes

• Services

• Histone Methylation

• Reagents

• Kits

• Instruments

• Enzymes

• Services

• Histone Acetylation

• Reagents

• Kits

• Instruments

• Enzymes

• Services

• Large Non-coding RNA

• Reagents

• Kits

• Instruments

• Enzymes

• Services

• Micro RNA Modification

• Reagents

• Kits

• Instruments

• Enzymes

• Services

• Chromatin Structures

• Reagents

• Kits

• Instruments

• Enzymes

• Services

Epigenetics Diagnostics Application Outlook (Revenue in USD Million; 2018 - 2030)

• Oncology

• Solid Tumors

• Others

• Non - Oncology

• Inflammatory Diseases

• Metabolic Diseases

• Infectious Diseases

• Cardiovascular Diseases

• Others

Epigenetics Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Epigenetics Diagnostics Market

• Roche Diagnostics

• Thermo Fisher Scientific, Inc.

• Eisai Co. Ltd.

• Novartis AG

• Element Biosciences, Inc.

• Dovetail Genomics LLC.

• Illumina, Inc.

• ValiRx Plc.

• Abcam plc.